Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based...

Area of Science:

• Cell Biology
• Molecular Biology
• Oncology

Background:

• The Transforming Growth Factor-beta (TGF-β) family comprises three distinct mammalian isoforms (TGF-β1, TGF-β2, TGF-β3), each with unique regulatory elements and critical physiological functions.
• Despite their essential roles in development and cellular processes, dysregulated TGF-β expression is implicated in diseases like fibrosis and cancer progression.
• Current therapeutic strategies often fail to differentiate between TGF-β isoforms, targeting all three collectively rather than specific deregulated ones.

Purpose of the Study:

• To provide a historical overview of the TGF-β field, emphasizing the often-overlooked unique functions of each isoform.
• To present the current landscape of TGF-β research, focusing on isoform-specific roles in disease pathology, particularly cancer.
• To critically evaluate existing TGF-β-targeted cancer therapies and advocate for refined, mechanism-based approaches.

Main Methods:

• Literature review and synthesis of existing research on TGF-β isoforms, their functions, and therapeutic targeting.
• Analysis of historical perspectives and current trends in TGF-β research.
• Evaluation of the efficacy and limitations of current TGF-β inhibitors in cancer treatment.

Main Results:

• Each TGF-β isoform (1, 2, and 3) possesses unique biological functions crucial for cell growth, immune response, and differentiation.
• Dysregulation of TGF-β signaling is a significant driver of pathological conditions, including fibrosis and tumor metastasis.
• Existing TGF-β inhibitors often lack specificity, targeting all isoforms and hindering therapeutic potential in cancer due to the need to preserve physiological roles.

Conclusions:

• A deeper understanding of isoform-specific TGF-β functions is critical for developing effective cancer therapies.
• Future therapeutic strategies must focus on targeting specific deregulated isoforms and disease-related pathway components.
• Mechanism-based and refined approaches are essential to enhance the efficacy of TGF-β-targeted cancer treatments while minimizing off-target effects.